Phase II Trial of Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1.
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2016
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms CTLA-4 NY-ESO-1
- 07 Jun 2017 Biomarkers information updated
- 11 Aug 2016 Status changed from active, no longer recruiting to completed.
- 09 Aug 2016 Trial was completed in Germany.